Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharming Group N.V (PHAR) Operating Income: 2018-2024

Historic Operating Income for Pharming Group N.V (PHAR) over the last 7 years, with Dec 2024 value amounting to -$8.6 million.

  • Pharming Group N.V's Operating Income rose 2096.11% to $90.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $104.8 million, marking a year-over-year increase of 442.95%. This contributed to the annual value of -$8.6 million for FY2024, which is 60.03% down from last year.
  • Per Pharming Group N.V's latest filing, its Operating Income stood at -$8.6 million for FY2024, which was down 60.03% from -$5.4 million recorded in FY2023.
  • Pharming Group N.V's Operating Income's 5-year high stood at $76.3 million during FY2020, with a 5-year trough of -$8.6 million in FY2024.
  • For the 3-year period, Pharming Group N.V's Operating Income averaged around $1.4 million, with its median value being -$5.4 million (2023).
  • As far as peak fluctuations go, Pharming Group N.V's Operating Income skyrocketed by 34.45% in 2022, and later slumped by 129.55% in 2023.
  • Yearly analysis of 5 years shows Pharming Group N.V's Operating Income stood at $76.3 million in 2020, then plummeted by 82.22% to $13.6 million in 2021, then spiked by 34.45% to $18.2 million in 2022, then crashed by 129.55% to -$5.4 million in 2023, then plummeted by 60.03% to -$8.6 million in 2024.